1. College of Pharmaceutical Science, Jilin University, Changchun 130021, China; 2. CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China; 3. Department of Biomaterials, College of Materials, Xiamen University, Xiamen, 361005, China; 4. University of Chinese Academy of Sciences, Beijing 100049, China. 5. QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, QLD 4029, Australia. 6. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD21231, USA.
✉ Corresponding authors: Guangjun Nie, Ph.D, National Center for Nanoscience and Technology (NCNST), China Email: niegjcn; Jingyan Wei, Ph.D, College of Pharmaceutical Science, Jilin University, Changchun, China Email: jingyanweijlueducom; Suping Li, Ph.D, National Center for Nanoscience and Technology (NCNST), China Email: lisupingcn.More
Citation:
Zhang Y, Wei J, Liu S, Wang J, Han X, Qin H, Lang J, Cheng K, Li Y, Qi Y, Anderson GJ, Sukumar S, Li S, Nie G. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics 2017; 7(5):1062-1071. doi:10.7150/thno.17908. https://www.thno.org/v07p1062.htm
Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.
Zhang, Y., Wei, J., Liu, S., Wang, J., Han, X., Qin, H., Lang, J., Cheng, K., Li, Y., Qi, Y., Anderson, G.J., Sukumar, S., Li, S., Nie, G. (2017). Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics, 7(5), 1062-1071. https://doi.org/10.7150/thno.17908.
ACS
Zhang, Y.; Wei, J.; Liu, S.; Wang, J.; Han, X.; Qin, H.; Lang, J.; Cheng, K.; Li, Y.; Qi, Y.; Anderson, G.J.; Sukumar, S.; Li, S.; Nie, G. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics 2017, 7 (5), 1062-1071. DOI: 10.7150/thno.17908.
NLM
Zhang Y, Wei J, Liu S, Wang J, Han X, Qin H, Lang J, Cheng K, Li Y, Qi Y, Anderson GJ, Sukumar S, Li S, Nie G. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics 2017; 7(5):1062-1071. doi:10.7150/thno.17908. https://www.thno.org/v07p1062.htm
CSE
Zhang Y, Wei J, Liu S, Wang J, Han X, Qin H, Lang J, Cheng K, Li Y, Qi Y, Anderson GJ, Sukumar S, Li S, Nie G. 2017. Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics. 7(5):1062-1071.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.